StubHub’s CEO has been holding off on taking the company public for three years, not out of hesitation but because he’s waiting for the right moment. After years of preparation, the online ticket giant might finally make its IPO move this summer—suggesting the timing now aligns with their strategy.

Editor’s Note: IPOs are a big deal, and timing can make or break them. StubHub’s cautious approach signals they’re playing the long game, waiting for market conditions to favor their debut. For investors and competitors, this could mean a major player is about to shake up the ticketing landscape—or reveal just how tricky going public really is.

Moleculin, a biotech company, just got a warning from Nasdaq for not meeting the stock exchange's listing requirements—specifically, their stock price has been trading below $1 for too long. They’ve got 180 days to get back in compliance, likely by doing a reverse stock split or boosting their share price.

Editor’s Note: This isn’t great news for Moleculin—Nasdaq warnings can spook investors and make it harder to raise money. But it’s not the end of the road; companies often fix this by consolidating shares. Still, it’s a red flag about the company’s financial health and could signal bigger struggles ahead. For biotech watchers, it’s a reminder of how volatile small-cap pharma stocks can be.